论文部分内容阅读
目的研究乳腺癌nm23基因、雌激素受体(Estrogen-receptor,ER)、孕激素受体(Progestin-receptor,PR)表达与组织学分级及预后关系。方法应用S-P免疫组织化学染色方法,研究转移性抑制基因nm23及雌孕激素受体在160例乳腺癌组织中的表达变化。结果nm23基因表达与乳腺癌病理组织学分级之间无显著相关性(P>0.05),而与淋巴结转移及预后有显著相关性(P<0.05)。乳腺癌有淋巴结转移组nm23基因阳性表达率明显低于无淋巴结转移组,而死亡率明显高于无淋巴结转移组。ER、PR阳性表达与乳腺癌病理组织学分级有显著相关性,即组织学分级愈低,ER、PR阳性表达率愈高。ER、PR阳性表达与淋巴结转移有显著相关性,(P<0.01),即有淋巴结转移者ER、PR阳性表达率低,无淋巴结转移者ER、PR阳性表达率高。ER、PR表达阳性组5年存活率明显高于ER、PR表达阴性组(P<0.05)。结论检测乳腺癌组织中的nm23基因及雌孕激素受体对临床正确判断乳腺癌病人的预后有一定的参考价值。
Objective To investigate the relationship between expression of nm23 gene, estrogen receptor (ER) and progestin-receptor (PR) and histological grade and prognosis in breast cancer. Methods The expression of metastasis suppressor gene nm23 and estrogen and progesterone receptors in 160 breast cancer tissues were studied by immunohistochemical staining with S-P. Results There was no significant correlation between nm23 gene expression and the histological grade of breast cancer (P>0.05), but there was significant correlation between lymph node metastasis and prognosis (P<0.05). The positive expression rate of nm23 in lymph node metastasis in breast cancer was significantly lower than that in no lymph node metastasis group, and the mortality was significantly higher than that in no lymph node metastasis group. There was a significant correlation between the positive expression of ER and PR and the histological grade of breast cancer. The lower the histological grade, the higher the positive rate of ER and PR. There was a significant correlation between the positive expression of ER and PR and lymph node metastasis (P<0.01), ie, the positive expression rates of ER and PR were low in patients with lymph node metastasis, and the positive rates of ER and PR in patients without lymph node metastasis were high. The 5-year survival rate of the ER and PR positive groups was significantly higher than that of the ER and PR negative groups (P<0.05). Conclusions The detection of nm23 gene and estrogen and progesterone receptors in breast cancer tissues have a certain reference value for clinically correct prognosis of breast cancer patients.